Cervical cancer screening and treatment in Uganda

Nakisige, Carolyn; Schwartz, Melissa; Ndira, anthony okoth

doi:10.1016/j.gore.2017.01.009

Cited by 113 publications

(139 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Reluctancy to screen, stigma, lack of awareness, chronic poverty, and inadequate medical services are largely responsible for the magnitude of the cancer epidemic in Uganda [9][10][11]. us, most cancer cases registered in hospitals are usually in their advanced stages that cannot be treated optimistically [12,13].…”

Section: Introductionmentioning

confidence: 99%

Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies

Omara

Kiprop

Ramkat

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The burden of neoplastic diseases is a significant global health challenge accounting for thousands of deaths. In Uganda, about 32,617 cancer cases were reported in 2018, accompanied by 21,829 deaths. In a view to identify some potential anticancer plant candidates for possible drug development, the current study was designed to compile the inventory of plants with reported anticancer activity used in rural Uganda and the evidences supporting their use in cancer therapy. An electronic survey in multidisciplinary databases revealed that 29 plant species belonging to 28 genera distributed among 24 families have been reported to be used in the management of cancer in Uganda. Anticancer plants were majorly from the families Bignoniaceae (7%), Caricaceae (7%), Fabaceae (7%), Moraceae (7%), and Rutaceae (7%). Most species occur in the wild (52%), though some are cultivated (48%). The growth habit of the plants is as trees (55%) or herbs (45%). Anticancer extracts are usually prepared from leaves (29%), bark (24%), roots (21%), and fruits (13%) through decoctions (53%), as food spices (23%) or pounded to produce ointments that are applied topically (10%). Prunus africana (Hook.f.) Kalkman, Opuntia species, Albizia coriaria (Welw. ex Oliver), Daucus carota L., Cyperus alatus (Nees) F. Muell., Markhamia lutea (Benth.) K. Schum., and Oxalis corniculata L. were the most frequently encountered species. As per global reports, Allium sativum L., Annona muricata L., Carica papaya L., Moringa oleifera Lam., Opuntia species, Prunus africana (Hook.f.) Kalkman, and Catharanthus roseus (L.) G. Don. are the most studied species, with the latter having vincristine and vinblastine anticancer drugs developed from it. Prostate, cervical, breast, and skin cancers are the top traditionally treated malignancies. There is a need to isolate and evaluate the anticancer potential of the bioactive compounds in the unstudied claimed plants, such as Cyperus alatus (Nees) F. Muell., Ficus dawei Hutch., Ficus natalensis Hochst., and Lovoa trichilioides Harms, and elucidate their mechanism of anticancer activity.

show abstract

Section: Introductionmentioning

confidence: 99%

Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies

Omara

Kiprop

Ramkat

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Many countries in SSA do not have screening programs and among those that do, coverage rates are frequently low [12,13]. In Uganda, lifetime screening rate estimations for cervical cancer are between 4.8% to 30% [13,14]. Mechanisms for quality assurance and invitations to screen are lacking in most of SSA [7].…”

Section: Cervical Cancer Screeningmentioning

confidence: 99%

“…Pap smears with cytological analysis [7], but SSA faces challenges in achieving high screening coverage with this method due to inadequate infrastructure and lack of trained personnel [1,14]. Alternative screening methods include visual inspection of the cervix with acetic acid (VIA) or Lugol's iodine (VILI), as well as HPV DNA testing [10].…”

Section: Cervical Cancer Screeningmentioning

confidence: 99%

Prevention of Cervical Cancer in Sub-Saharan Africa: the Promises and Challenges of HPV Vaccination

Black¹,

Richmond²

2018

Preprint

View full text Add to dashboard Cite

Abstract:In sub-Saharan Africa (SSA), cervical cancer is a critical public health issue; it is the second leading cause of cancer among women and the leading cause of female cancer deaths. Incidence and mortality rates are substantially higher than in high-income countries with population-based screening programs, yet implementing screening programs in SSA has so far proven to be challenging due to financial, logistical and sociocultural factors. Human Papillomavirus (HPV) vaccination is an effective approach for primary prevention of cervical cancer and presents an opportunity to reduce the burden from cervical cancer in SSA. With a number of SSA countries now eligible for GAVI support for vaccine introduction, it is timely to consider the factors that impede and facilitate implementation of vaccine programs in SSA. This article reviews the epidemiological and clinical features of cervical cancer in SSA and describes the current status of HPV vaccine implementation in SSA countries. The review considers the challenges that will need to be addressed, and effective approaches to the design and implementation of HPV vaccination programs, using Rwanda as a case study. The review aims to provide suggestions and guidance to those involved in the development and implementation of HPV vaccination programs in SSA.

show abstract

“…In sub-Saharan Africa, treatments like radiation therapy and other surgical procedures are not fully utilised because of lack of equipment and qualified personnel, hence little has been documented on which treatment procedures are being used for cervical cancer in HIV-seropositive women [8]. There is lack of evidence-based guidelines and strategies for screening, vaccination against HPV, prevention and treatment of cervical cancer in HIV-seropositive women in most developed countries [9, 10]. Coupled with this, there is little rigorous evidence on the global epidemiology of the treatment of cervical cancer in HIV-seropositive women [8].…”

Section: Introductionmentioning

confidence: 99%

Treatment of cervical cancer in HIV-seropositive women from developing countries: a protocol for a systematic review

2018

View full text Add to dashboard Cite

BackgroundCervical cancer has become the most common cancer affecting women in Africa. Significantly, 85% of these annual deaths occur in the developing world, with the majority being middle-aged women. Research has shown that in sub-Saharan Africa, cervical cancer trends are on the rise in the past two decades because of HIV and this has resulted in an increase in cervical cancer cases among young women. However, little or no information exists that has shown that any of the available treatment methods are more effective than others when it comes to treating cervical cancer in HIV-seropositive women. The aim of this protocol is to offer a plan on how to systematically review cervical cancer treatment methods available for HIV-seropositive women in developing countries.Methods/designThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement was used to develop the protocol for the systematic review which will be reported in accordance with the PRISMA guidelines. A number of databases, Embase, MEDLINE, PubMed, CINAHL and Cochrane Library, will be searched for relevant studies, and citation and reference list tracking will be used to search for additional studies. Prospective and retrospective cohort studies, case-control, randomised controlled trials and cross-sectional studies that were carried out in and for the developing world will be eligible for inclusion. Peer-reviewed studies and grey literature examining cervical cancer treatment modalities in HIV-seropositive women will be included. Descriptive statistics and tables will be used to summarise results, and meta-analysis will be used where appropriate.DiscussionThe review findings will provide the current picture of the existing treatment methods being used to treat cervical cancer in HIV-seropositive women in developing countries. The findings might be used for the establishment of evidence-based guidelines for treatment of cervical cancer in seropositive women as well as prompt policy-makers and governments to decide and support future research in a way to find a lasting solution.Systematic review registrationPROSPERO CRD42017054676 https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=54676 Electronic supplementary materialThe online version of this article (10.1186/s13643-018-0686-9) contains supplementary material, which is available to authorized users.

show abstract

Cervical cancer screening and treatment in Uganda

Cited by 113 publications

References 12 publications

Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies

Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies

Prevention of Cervical Cancer in Sub-Saharan Africa: the Promises and Challenges of HPV Vaccination

Treatment of cervical cancer in HIV-seropositive women from developing countries: a protocol for a systematic review

Contact Info

Product

Resources

About